Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan

Overview of attention for article published in Japanese Journal of Radiology, September 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 10 publications that cite this research output.

10

The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.

Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager

Article in Diagnostics (July 2022)

The Pattern of Use, Effectiveness, and Safety of Gadoteric Acid (Clariscan) in Patients Undergoing Contrast-Enhanced Magnetic Resonance Imaging: A Prospective, Multicenter, Observational Study

Article in Contrast Media & Molecular Imaging (October 2021)

The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis

Article in European Radiology Experimental (October 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.